Jubilant Organosys and its two subsidiaries viz, Jubilant Biosys Ltd (JBL) and Jubilant Chemsys Ltd (JCL) have entered into three way drug discovery partnership with Orion Corporation, a leading pharmaceutical company of Finland. Under this 'Hybrid & Integrated' arrangement, Orion will have the option of utilizing resources flexibly from both JBL and JCL based on the requirements of its drug discovery projects.

Commenting on the development, Mosur, CEO and president, JBL, said, "We are very pleased to partner with Orion and offer our integrated discovery services enabling the discovery efforts at Orion. Jubilant's Flexible and Hybrid platform of innovative discovery chemistry, biology and insilico services demonstrates its ability to customize and accelerate global drug discovery efforts. It will be our continued endeavour to enable creatie partnering models supporting our scientific capabilities."

This arrangement bears testimony to the expertise of JBL and JCL scientists. A strong team comprising Biologists and Chemists will be engaged in carrying our research on Orion's projects at the two subsidiaries as per the need of the projects.

Dr Antti Haapalinna, vice president, Research, R&D of Orion Corporation, said, " We are happy to partner with Jubilant and are confident of scaling up our drug discovery programs with support from their scientific team. Through this partnership, we would achieve a good basis for success as it would complement our in-house discovery effort."